Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corona RemediesNSE:CORONA +0.37%18 Net Margin % is 12.84% as of Mar. 2026, which is 16% above its 10-year median of 11.06. GuruFocus rates NSE:CORONA with a GF Score™ of 18/100. The stock has 3 warning signs investors should review. Among 962 Drug Manufacturers companies, Corona Remedies ranks better than 73.18% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Corona Remedies's Net Income for the
three
months ended in Mar. 2026 was ₹453 Mil. Corona Remedies's Revenue for the
three
months ended in Mar. 2026 was ₹3,531 Mil. Therefore, Corona Remedies's net margin for the quarter that ended in Mar. 2026 was 12.84%.
The historical rank and industry rank for Corona Remedies's Net Margin % or its related term are showing as below:
NSE:CORONA'
s Net Margin % Range Over the Past 10 Years
Min: 8.93 Med: 11.06 Max: 13.21
Current: 12.75
NSE:CORONA's Net Margin % is ranked better than 73.18% of 962
companies
in the Drug Manufacturers industry
Industry Median: 5.435
vs NSE:CORONA: 12.75
Corona Remedies (NSE:CORONA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Corona Remedies Net Margin % Related Terms
Corona Remedies Net Margin % Historical Data
* Premium members only.
The historical data trend for Corona Remedies's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:CORONA vs LLY, JNJ, ABBV: Net Margin % Comparison
For the Drug Manufacturers - General subindustry, Corona Remedies's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corona Remedies Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Corona Remedies's Net Margin % distribution charts can be found below:
* The bar in red indicates where Corona Remedies's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corona Remedies (NSE:CORONA) has a Net Margin % of 12.84% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Corona Remedies and its competitors. This is 16% above median its historical median of 11.06. Over the past decade, Corona Remedies' Net Margin % has ranged from 8.93 to 13.21. According to the industry distribution chart, Corona Remedies ranks #258 out of 962 companies in the Drug Manufacturers industry, placing it in the top 26.8%.
Is Corona Remedies' Net Margin % too high?
Corona Remedies' current Net Margin % of 12.84% is 16% above median its 10-year median of 11.06. Over the past 10 years, this metric has ranged from a low of 8.93 to a high of 13.21. The Drug Manufacturers industry median Net Margin % is 5.44. Corona Remedies' value of 12.84% is 136.2% above this industry median. Based on the distribution chart, Corona Remedies ranks #258 out of 962 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Corona Remedies has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Corona Remedies' Net Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Corona Remedies ranks #258 out of 962 companies for Net Margin %. This puts Corona Remedies in the upper half of its industry. The industry median Net Margin % is 5.44. Corona Remedies' value of 12.84% is 136.2% above this benchmark. Historically, Corona Remedies' own Net Margin % has ranged from 8.93 to 13.21 over the past decade. While the company's 10-year median is 11.06 vs. the industry median of 5.44, Corona Remedies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.44, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Corona Remedies's current Net Margin % of 12.84% is 136.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Corona Remedies and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corona Remedies's current Net Margin % is 12.84%, which is 16% above median its own 10-year median of 11.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corona Remedies stock overvalued right now?
Corona Remedies (NSE:CORONA) has a current Net Margin % of 12.84%. The current Net Margin % is 12.84%, which is 16% above median its 10-year median of 11.06 and 136.2% above the Drug Manufacturers industry median of 5.44. Corona Remedies' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Corona Remedies (NSE:CORONA), the current Net Margin % is 12.84% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Corona Remedies Ltd is mainly engaged in the business of manufacturing, trading and marketing of Pharmaceutical products. It is engaged in developing, manufacturing and marketing products in women's healthcare, cardio-diabetes, pain management, urology and other segments, such as Vitamin Minerals and Nutrients(VMN), gastrointestinal and respiratory therapies. The company's brands are B-29, myoril, Tricium, Cortel, and Obimet. The Company has only one reportable business segment i.e. Pharmaceuticals. The company has presence in India as well as Outside India. The company generates majority of revenue from India.
18GF Score
Get the complete analysis for NSE:CORONA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:CORONA has been successfully added to your 
